Cancer Letters
Volume 203, Issue 2 , Pages 155-161 , January 2004

Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro

  • Jinsoo Chung

      Affiliations

    • Urologic Oncology Clinic, National Cancer Center, Goyang, South Korea
    • ,
  • Cheol Kwak

      Affiliations

    • Department of Urology, Seoul National University College of Medicine, Seoul National University Hospital, 28 Yongon Dong, Jongno Ku, Seoul, 110-744, South Korea
    • Clinical Research Institute, Seoul National University Hospital, 28 Yongon Dong, Jongno Ku, Seoul, 110-744, Seoul, South Korea
    • ,
  • Ren Jie Jin

      Affiliations

    • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
    • ,
  • Chang-Ho Lee

      Affiliations

    • Department of Urology, Soonchunhyang University College of Medicine, Cheonan, South Korea
    • ,
  • Kang Hyun Lee

      Affiliations

    • Urologic Oncology Clinic, National Cancer Center, Goyang, South Korea
    • ,
  • Sang Eun Lee

      Affiliations

    • Department of Urology, Seoul National University College of Medicine, Seoul National University Hospital, 28 Yongon Dong, Jongno Ku, Seoul, 110-744, South Korea
    • Cancer Research Center, Clinical Research Institute, Seoul National University Hospital, 28 Yongon Dong, Jongno Ku, Seoul, 110-744, South Korea
    • Corresponding Author InformationCorresponding author. Address: Department of Urology, Seoul National University College of Medicine, Seoul National University Hospital, 28 Yongon Dong, Jongno Ku, Seoul, 110-744, Seoul, South Korea. Tel.: +82-2-760-2408; fax: +82-2-742-4665

Received 24 February 2003 ,Accepted 17 July 2003.

References 

  1. Thurman SA, De Weese TL. Multimodality therapy for the treatment of muscle-invasive bladder cancer. Semin. Urol. Oncol. 2000;18:313–322
  2. Roth BJ, Bajorin DF. Advanced bladder cancer: the need to identify new agents in the post M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin). World J. Urol. 1995;153:894–900
  3. Sternberg CN, Calabro F. Chemotherapy and management of bladder tumors. BJU Int. 2000;85:599–610
  4. Jones SE, Jomary C. Clusterin. Int. J. Biochem. Cell Biol. 2002;34:427–431
  5. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 1995;27:633–645
  6. Kyprianou N, English HF, Davison NE, Issac JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 1991;51:162–166
  7. Wright PS, Cross-Doersen D, Th'ng JP, Guo XW, Crissman HA, Bradbury EM, et al  A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp. Cell Res. 1996;222:54–60
  8. Schwochau GB, Nath KA, Rosenberg ME. Clusterin protects against oxidative stress in vitro through aggressive and nonaggressive properties. Kidney Int. 1998;53:1647–1653
  9. French LE, Wohlwend A, Sappino AP, Tschopp J, Schifferli JA. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J. Clin. Invest. 1994;93:877–884
  10. Viard I, Wehrli P, Jornot L, Bullani R, Vechietti JL, Schifferli JA, et al. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J. Invest. Dermatol. 1999;112:290–296
  11. Lee C, Janulis K, Ilio A, Shah I, Park S, Kim V, et al. In vitro models of prostate apoptosis: clusterin as an antiapoptotic mediator. Prostate Suppl. 2000;9:21–24
  12. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 1997;3:1707–1711
  13. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message −2 is an antiapoptotic gene involved in progression to androgen-independence in prostate cancer. Cancer Res. 2000;60:170–176
  14. Miyake H, Hara S, Arakawa S, Kamidono S, Hara I. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J. Urol. 2002;167:703–706
  15. Miyake H, Gleave ME, Arakawa S, Kamidomi S, Hara I. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potentials. J. Urol. 2002;167:2003–2008
  16. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 2000;157:393–399
  17. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptic gene clusterin. Neoplasia. 2001;3:360–367
  18. Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology. 2001;Suppl. 58:39–49
  19. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al.  Methtrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of urothelium. Efficacy, patterns of response and relapse. Cancer. 1989;64:2448–2458
  20. Marshall JL, Andrews PA. Preclinical and clinical experience with cisplatin resistance. Hemat. Oncol. Clin. Nor. Am. 1995;9:415–427
  21. Vaughan DJ, Malkowiccz S. Recent advances in bladder cancer chemotherapy. Cancer Investig. 2001;19:77–85
  22. Chu G, Mantin R, Shen YM, Baskett G. Massive cisplatin overdose by accidental substitution for carboplatin: toxicity and management. Cancer. 1993;72:3707–3714
  23. Vogelzang NJ, Stadler WM. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology. 1999;53:243–250
  24. Sintich SM, Steinberg J, Kozlowski JM, Lee C, Pruden S, Sayeed S, et al. Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate. 1999;29:87–93
  25. Humphreys D, Hochgrebe TT, Easterbrook-Smith SB, Tenniswood MP, Wilson MR. Effects of clusterin overexpression on TNFalpha- and TGFbeta-mediated death of L929 cells. Biochemistry. 1997;36:15233–15243
  26. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidino S. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. J. Urol. 1999;162:2176–2178
  27. Hong JH, Lee E, Hong J, Shin YJ, Ahn J. Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int. 2002;90:113–117
  28. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemosensitization and inhibition of tumor growth and metastasis by antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 2001;7:4245–4252

PII: S0304-3835(03)00690-6

doi: 10.1016/j.canlet.2003.07.008

Cancer Letters
Volume 203, Issue 2 , Pages 155-161 , January 2004

Article Tools

* Image Usage & Resolution